Market insight – The medical products, supplies and distribution sector
Structural value, predictable earnings and strategic opportunity are the factors increasingly enticing buyers to the UK medical products, supplies and distribution sector.
With reliability, cost pressures and consolidation at the forefront of the market, healthcare providers want to rely on a smaller core of suppliers. This means distributors are expected to hold stock locally, supply consistently and help manage inventory on behalf of hospitals and care providers, rather than simply delivering boxes.
Businesses offering strong logistics, repeat-order contracts and embedded supply relationships are becoming more valuable.
This is keeping the sector firmly on the radar of strategic buyers and investors, with continued consolidation expected as acquirers look to scale, strengthen coverage and lock in long-term healthcare demand.
Factors driving growth
1. Strong healthcare demand
The ageing population and ongoing management of chronic conditions continue to increase demand for consumables, disposables and essential medical supplies across acute and community care settings.
2. NHS procurement focus
Large-scale NHS frameworks and coordinated procurement are driving volume certainty. Framework agreements, national contracts and group purchasing give larger distributors stronger visibility and scale.
3. Shift to outsourced supply solutions
Health systems want distributors to do more than deliver stock – they want inventory planning, ward replenishment, barcode traceability and timely delivery. This expands service revenue and deepens customer relationships.
4. Standardisation and value contracts
Trusts are moving towards agreed standard ranges and long-term pricing commitments to reduce cost and complexity. Distributors that align with formularies are winning larger, stable volumes.
5. Regulatory and quality requirements
Stronger compliance expectations for traceability, audit trails and documentation mean distributors with certified quality processes are preferred partners, driving competitive advantage.
6. Digital ordering & logistics investment
Cloud-based ordering, integrated stock management and enhanced logistics capability improve service levels and create differentiation in a crowded market.
7. Sustainability expectations
Green logistics, reduced packaging and ethical sourcing are increasingly factored into procurement decisions, especially in public sector contracts.
8. Private sector healthcare growth
Growth in private medical procedures and elective care translates into higher demand for non-NHS supply channels and specialist products.
Current landscape
A sizeable and growing market: The UK hospital supplies market alone is valued at around $8.16bn in 2026 and is forecast to grow to around $10.3bn by 2031 at a ~4.8% CAGR, supported by steady demand for disposables, infection-control products and equipment refresh cycles.
Disposable consumables still account for the largest share, while sterilisation and disinfection equipment are among the faster-growing segments. NHS acute hospitals remain the dominant customer base, with private hospitals growing at a quicker pace.
NHS procurement still shapes distribution: The NHS Supply Chain plays a central role in how products are bought and distributed nationwide. It manages tenders and frameworks for clinical consumables, medical devices and capital equipment, with long contracting cycles which set the tone for supplier competition and pricing.
Regulatory and supply pressures persist: Products sold in the UK market require careful regulatory oversight – distributors must navigate certification, traceability and quality requirements. This complexity favours experienced partners with strong compliance capabilities. Broader supply pressures, including logistical challenges and medicine shortages, continue to influence buying patterns and inventory strategies.
Competitive dynamics and integration: Distribution is no longer a simple wholesaling business. Market players are integrating closer with manufacturers, providers and procurement teams to offer inventory support, data-driven stock management and just-in-time delivery models. Large global wholesalers still have scale advantages, but UK-focused specialists that can tailor service and range to local needs are competitive.
M&A activity continues to rise
Clear demand fundamentals make the sector attractive – the NHS and private healthcare providers need reliable supply of consumables, devices and logistics services year-on-year. That creates recurring revenue, long contract tails and high retention, which drives valuation confidence.
Scale and consolidation economics are increasingly important. Larger buyers (both strategic groups and private equity) are willing to pay a premium to:
- Widen geographic reach
- Expand category breadth (e.g. combining high-volume consumables with specialist devices)
- Achieve operational efficiencies through shared warehousing, IT platforms and centralised procurement.
Buyers are also seeking value-added services – inventory management, data analytics, last-mile fulfilment – which differentiate traditional distribution. Acquiring businesses with these capabilities accelerates growth without building from scratch.
Regulatory complexity and compliance costs act as a barrier to entry for smaller operators. Well-governed distributors with robust quality systems and ISO/RegOps credentials are therefore attractive targets as they are harder for competitors to replicate quickly.
And capital markets remain supportive. Debt markets for healthcare assets are open and there is strong interest from both UK and international investors for defensive, cash-generative businesses with structural tailwinds.
Factors driving higher valuations and EBITDA multiples
In the UK medical products, supplies and distribution space, we have seen deal values that have been calculated on adjusted EBITDA/earnings multiples ranging from 5/6x to double-digit figures, depending on various factors such as:
Quality and visibility of earnings: Businesses with recurring revenues, repeat ordering and contracted or framework-led income command higher multiples due to predictability and resilience.
Customer mix and stickiness: Exposure to NHS frameworks, long-term private hospital contracts or sole-supplier arrangements materially increases value. Low customer churn and embedded supply relationships are key.
Scale and operational leverage: Larger distributors benefit from purchasing power, logistics efficiency and margin resilience. Size also supports national framework participation, which buyers will pay for.
Product mix and margin profile: Higher-margin consumables, specialist or regulated products, and own-label/private-label ranges attract stronger valuations than commoditised distribution alone.
Value-added services: Inventory management, logistics integration, data-driven stock control and last-mile fulfilment capabilities lift multiples by moving the business beyond pure wholesale.
Regulatory strength and governance: Robust quality systems, traceability and compliance reduce risk and create barriers to entry. Well-run, audit-ready businesses are significantly more attractive to acquirers.
Growth headroom: Clear opportunities to expand geographically, cross-sell products, win new frameworks or consolidate fragmented niches support premium pricing.
Strategic fit for the buyer: Where a target strengthens a buyer’s footprint, fills a product gap or accelerates a buy-and-build strategy, competitive tension can push valuations into double-digit territory.
Management depth and succession: A capable second-tier management team and low founder dependency reduce integration risk and support higher multiples.
M&A interest from acquirers & investment routes
Trade & strategic buyers
Large UK and international distributors, manufacturers and healthcare services groups are actively acquiring to increase scale, widen product range and strengthen national coverage. Targets that provide access to NHS frameworks, specialist product categories or value-added logistics services are particularly attractive, as acquisitions accelerate growth faster than organic expansion.
Manufacturer-led acquisitions
Manufacturers are buying distributors to secure routes to market, improve margin capture and gain closer control over customer relationships. This is especially relevant in consumables and regulated products, where continuity of supply and customer access are critical.
Private equity-backed platforms
Private equity remains highly active, backing platform distributors and pursuing buy-and-build strategies in fragmented sub-sectors. The focus is on recurring revenues, operational leverage and bolt-on opportunities that drive multiple expansion on exit.
International buyers
Overseas groups (US and European) continue to target UK distributors due to the scale and stability of the NHS market. Acquisitions provide immediate market entry, regulatory infrastructure and local logistics capability.
Minority investment and growth capital
For some businesses, minority investment is being used to fund warehouse expansion, systems upgrades or geographic growth ahead of a future full exit. This route suits management teams looking to de-risk while retaining control.
Which companies in this sector have been sold by KBS Corporate?
AMPCS and Kalon Biological acquired by Calibre Scientific
Essex-based analytical instruments supplier AMPCS and Surrey-based medical diagnostic kit producer Kalon Biological were both acquired by Calibre Scientific, a diversified global provider of life science tools and diagnostics.
Sumed International acquired by Direct Healthcare Group (DHG)
Derbyshire-based Sumed, a manufacturer, supplier and distributor of medical equipment and treatments, was sold to South Wales-based DHG in a deal designed to expand the acquirer’s comprehensive pressure ulcer prevention portfolio.
Alterior acquired by Medray Imaging Systems
Alterior, a Plymouth-based company which provides medical and dental diagnostic X-ray imaging systems, was sold to Dublin-based Medray, the leading provider of radiology equipment, accessories and consumables in Ireland.
Leca Dental Laboratory acquired by Ansor Ventures
Glasgow-based Leca Dental, a full-service laboratory producing implants, prosthetic dentures, crown and bridge, chrome cobalt and orthodontic products, was acquired by Amalgamated Laboratory Solutions, a portfolio company of private equity firm Ansor.
Avensys acquired by HERMED Technische Beratung
Kidderminster-based Avensys, which provides bio-medical equipment across a wide range of healthcare settings, was sold to HERMED, part of the VAMED Group, a leading provider of international healthcare headquartered in Vienna.
SterileFLAT antibacterial acquired by Admor
SterileFLAT, a Berkshire-based manufacturer and supplier of peripheral IT products to the medical sector including medical keyboards, mice and mouse mats, was sold to Admor, a supplier of products to dental practices.
If you are a shareholder of a medical products, supplies and distribution company, we would be keen to speak with you regarding your potential exit or succession plans. If you are open to exploring this avenue or have any questions, please do not hesitate to call us on 0161 222 0072.